Terms: = Liver cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
28 results:
1. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases.
Zhang C; Wang XY; Zuo JL; Wang XF; Feng XW; Zhang B; Li YT; Yi CH; Zhang P; Ma XC; Chen ZM; Ma Y; Han JH; Tao BR; Zhang R; Wang TQ; Tong L; Gu W; Wang SY; Zheng XF; Yuan WK; Kan ZJ; Fan J; Hu XY; Li J; Zhang C; Chen JH
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759015
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients.
Chiang SF; Huang HH; Tsai WS; Chin-Ming Tan B; Yang CY; Huang PJ; Yi-Feng Chang I; Lin J; Lu PS; Chin E; Liu YH; Yu JS; Chiang JM; Hung HY; You JF; Liu H
Biomed J; 2022 Apr; 45(2):347-360. PubMed ID: 35550340
[TBL] [Abstract] [Full Text] [Related]
3. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract] [Full Text] [Related]
4. Molecular genomic landscapes of hepatobiliary cancer.
Shibata T; Arai Y; Totoki Y
Cancer Sci; 2018 May; 109(5):1282-1291. PubMed ID: 29573058
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract] [Full Text] [Related]
6. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal cancer.
Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
[No Abstract] [Full Text] [Related]
7. Genomic Profiling of Biliary Tract cancers and Implications for clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract] [Full Text] [Related]
8. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening kras-focused clinical view.
Bencsikova B; Bortlicek Z; Halamkova J; Ostrizkova L; Kiss I; Melichar B; Pavlik T; Dusek L; Valik D; Vyzula R; Zdrazilova-Dubska L
BMC Gastroenterol; 2015 Mar; 15():37. PubMed ID: 25888291
[TBL] [Abstract] [Full Text] [Related]
10. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract] [Full Text] [Related]
11. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract] [Full Text] [Related]
12. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
[TBL] [Abstract] [Full Text] [Related]
13. Impact of early tumor shrinkage on clinical outcome in wild-type-kras colorectal liver metastases treated with cetuximab.
Ye LC; Wei Y; Zhu DX; Chen T; Xu J
J Gastroenterol Hepatol; 2015 Apr; 30(4):674-9. PubMed ID: 25387601
[TBL] [Abstract] [Full Text] [Related]
14. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on kras mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract] [Full Text] [Related]
15. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.
Yaeger R; Cercek A; Chou JF; Sylvester BE; Kemeny NE; Hechtman JF; Ladanyi M; Rosen N; Weiser MR; Capanu M; Solit DB; D'Angelica MI; Vakiani E; Saltz LB
Cancer; 2014 Aug; 120(15):2316-24. PubMed ID: 24737664
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic relevance of kras genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.
Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
Int J Oncol; 2014 Jun; 44(6):1820-30. PubMed ID: 24715238
[TBL] [Abstract] [Full Text] [Related]
17. [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma].
Sevčíková K; Ušáková V; Bartošová Z; Sabol M; Ondrušová M; Ondruš D; Spánik S
Klin Onkol; 2014; 27(1):38-44. PubMed ID: 24635436
[TBL] [Abstract] [Full Text] [Related]
18. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract] [Full Text] [Related]
19. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
Biomed Res Int; 2013; 2013():143273. PubMed ID: 24307987
[TBL] [Abstract] [Full Text] [Related]
20. The frequency of kras and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
Robertson S; Hyder O; Dodson R; Nayar SK; Poling J; Beierl K; Eshleman JR; Lin MT; Pawlik TM; Anders RA
Hum Pathol; 2013 Dec; 44(12):2768-73. PubMed ID: 24139215
[TBL] [Abstract] [Full Text] [Related]
[Next]
